Edition:
United States

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

8.45USD
3:59pm EST
Change (% chg)

$0.14 (+1.68%)
Prev Close
$8.31
Open
$8.30
Day's High
$8.51
Day's Low
$8.01
Volume
56,786
Avg. Vol
64,606
52-wk High
$21.30
52-wk Low
$3.13

Latest Key Developments (Source: Significant Developments)

Catalyst biosciences Q3 loss per share $1.34
Thursday, 2 Nov 2017 08:30am EDT 

Nov 2 (Reuters) - Catalyst Biosciences Inc :Catalyst Biosciences reports third quarter 2017 operating & financial results and provides corporate update.Q3 loss per share $1.34.Catalyst Biosciences Inc - ‍phase 1/2 trial of factor IX CB 2679D is advancing with interim results expected by year-end​.Catalyst Biosciences Inc - ‍phase 2 trial of factor Fviia Marzeptacog Alfa (activated) on track for initiation by year-end​.Catalyst Biosciences- ‍believes existing capital resources will be sufficient to meet its projected operating requirements for at least next 12 months​.  Full Article

Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration
Tuesday, 24 Oct 2017 08:00am EDT 

Oct 24 (Reuters) - Catalyst Biosciences Inc ::Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration to develop intravitreal anti-complement factor 3 (c3) products for the treatment of dry amd and other retinal diseases.Catalyst Biosciences - ‍under terms of agreement, co, mosaic will collaborate to improve pharmacokinetic (pk) properties of co's anti-c3 proteases​.Catalyst Biosciences Inc - ‍will retain global commercial rights for all collaboration products​.Catalyst Biosciences Inc - ‍for all collaboration products, mosaic will receive product sublicense fees and/or milestone payments and royalties​.  Full Article

Catalyst Biosciences Inc - ‍companies plan to have interim, top-line results by end of 2017
Tuesday, 26 Sep 2017 08:00am EDT 

Sept 26 (Reuters) - Catalyst Biosciences Inc :Catalyst Biosciences granted FDA orphan drug designation for subcutaneous recombinant human Factor IX variant for treatment of hemophilia B.Catalyst Biosciences Inc - ‍companies plan to have interim, top-line results by end of 2017 and complete trial results in early 2018​.  Full Article

Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial
Monday, 25 Sep 2017 08:01am EDT 

Sept 25 (Reuters) - Catalyst Biosciences Inc :Catalyst Biosciences announces successful completion of first subcutaneous dosing cohort in ongoing hemophilia B clinical trial.Catalyst Biosciences Inc - ‍companies plan to have interim top-line data from trial by end of 2017​.Catalyst Biosciences- ‍announced collaborator Isu Abxis completed dosing of first subcutaneous cohort in ongoing Phase 1/2 proof-of-concept clinical trial.  Full Article

Catalyst Biosciences Inc announces issuance of Asia patents covering Factor IX Hemophilia Program
Monday, 11 Sep 2017 08:01am EDT 

Sept 11 (Reuters) - Catalyst Biosciences Inc :Catalyst Biosciences Inc - announces issuance of Asia patents covering factor IX Hemophilia Program.  Full Article

Catalyst Biosciences' reports positive data on hemophilia B drug
Wednesday, 6 Sep 2017 08:01am EDT 

Sept 6 (Reuters) - Catalyst Biosciences Inc :Catalyst Biosciences announces positive factor ix clinical data.Catalyst Biosciences-positive clinical data from 1st cohort of ongoing phase 1/2 proof-of-concept clinical trial in individuals with severe hemophilia b.Catalyst Biosciences Inc - interim, top-line results of the open-label study are expected by end of 2017 and complete trial results in early 2018.Catalyst Biosciences Inc - ‍ potency results are consistent with company's earlier research​.  Full Article

Catalyst Biosciences posts Q2 loss of $2.53 per share
Thursday, 3 Aug 2017 08:00am EDT 

Aug 3 (Reuters) - Catalyst Biosciences Inc :Catalyst biosciences reports second quarter 2017 financial results and provides subcutaneous (sq) hemophilia program update.Q2 loss per share $2.53.Catalyst biosciences inc - ‍cash, cash equivalents and short-term investments as of june 30, 2017 were $32.4 million​.Catalyst biosciences inc - believes existing capital resources will be sufficient to meet projected operating requirements for at least next 12 months​.  Full Article

Financial milestone achieved in Catalyst's subcutaneous factor IX program
Thursday, 6 Jul 2017 08:01am EDT 

July 6 (Reuters) - Catalyst Biosciences Inc ::Financial milestone achieved in Catalyst's subcutaneous factor IX program.Catalyst Biosciences Inc - achieved a financial milestone under its collaboration with ISU ABXIS.Catalyst Biosciences Inc - ISU ABXIS and Catalyst plan to have top-line data from clinical trial by end of 2017 for CB 2679d/ISU304.  Full Article

Catalyst Biosciences' Factor IX granted orphan drug designation in Europe
Wednesday, 28 Jun 2017 08:00am EDT 

June 28 (Reuters) - Catalyst Biosciences Inc :Catalyst Biosciences' Factor IX granted orphan drug designation in Europe.Catalyst Biosciences - European Commission granted orphan medicinal product designation to CB 2679d/ISU304, clinical stage drug candidate for hemophilia B.  Full Article

Catalyst Biosciences and ISU Abxis complete dosing of first patient cohort in Hemophilia B clinical trial
Wednesday, 14 Jun 2017 08:01am EDT 

June 14 (Reuters) - Catalyst Biosciences Inc :Catalyst Biosciences and ISU Abxis complete dosing of first patient cohort in Hemophilia B clinical trial.Says plans to have top line data from in Hemophilia B clinical trial by end of 2017.  Full Article

BRIEF-Catalyst biosciences Q3 loss per share $1.34

* Catalyst Biosciences reports third quarter 2017 operating & financial results and provides corporate update